Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56

Area of Science:

• Molecular Biology
• Structural Biology
• Cancer Research

Background:

• Protein phosphatase 2A (PP2A) is a crucial human tumor suppressor.
• Cancerous inhibitor of PP2A (CIP2A) promotes cancer by inhibiting PP2A and activating oncogenic pathways.
• The structural basis of CIP2A-PP2A interaction remained unknown.

Purpose of the Study:

• To elucidate the 3D structure of CIP2A and its interaction mechanism with PP2A.
• To investigate the role of CIP2A homodimerization in its function.
• To identify potential therapeutic targets for CIP2A in cancer treatment.

Main Methods:

• Yeast two-hybrid assays for interaction studies.
• X-ray crystallography to determine the structure of a CIP2A fragment.
• Structure-based mutational analysis to probe the dimerization interface.
• Expression analysis of PP2A subunits B56α and B56γ.

Main Results:

• CIP2A forms homodimers, confirmed by structural and mutational analyses.
• The crystal structure of the N-terminal CIP2A fragment (1-560) was solved at 3.0 Å resolution.
• CIP2A dimer binds to PP2A subunits B56α and B56γ via a conserved N-terminal region.
• Dimerization enhances CIP2A binding to B56 proteins.
• Inhibition of CIP2A dimerization or B56α/γ expression leads to CIP2A destabilization and degradation.

Conclusions:

• This study provides the first structure-function analysis of CIP2A interaction with PP2A/B56.
• CIP2A homodimerization is critical for its binding to PP2A and oncogenic function.
• Targeting CIP2A dimerization or B56 expression offers novel therapeutic avenues for cancer treatment.